# Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

> **NCT00985127** · PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 99 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** placebo
- **DRUG:** BCX4208

## Key facts

- **NCT ID:** NCT00985127
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2012-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985127, "Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00985127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*